Please ensure Javascript is enabled for purposes of website accessibility

Neurocrine Biosciences Q1 Beats on Earnings, Revenue

By Eric Volkman - May 7, 2020 at 7:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's Ingrezza continues to power its revenue and profitability growth.

Investors rewarded Neurocrine Biosciences (NBIX 1.27%) on Wednesday for posting a Q1 of fiscal 2020 earnings report that featured encouraging growth in key financials.

The biotech company published the quarterly release after market hours on Tuesday, revealing that it booked revenue of $237.1 million -- 71% higher than the Q1 of fiscal 2019 figure. On the bottom line, under GAAP standards, the company flipped to a net profit of $37.4 million, or $0.39 per share, from a year-ago loss of $102.1 million. Non-GAAP (adjusted) net income nearly tripled, to $79.1 million.

Pharmacist discussing medication with a patient.

Image source: Getty Images.

That performance was mixed, as far as analyst estimates go. On average, prognosticators following the stock believed Neurocrine would post sales of just over $138 million and per-share GAAP net income of just under $0.66.

The company's robust growth was almost entirely due to increased sales of the very successful Ingrezza, its treatment for tardive dyskinesia (a disorder in which a patient suffers from involuntary body motions). Since Ingrezza sales comprised more than 97% of Neurocrine's revenue, the company's fortunes have depended on the performance of the drug.

That will end soon, however. Late last month, Neurocrine won Food and Drug Administration (FDA) approval for Ongentys, a once-per-day, add-on pill that treats Parkinson's disease. Although the company is delaying the commercial launch of Ongentys due to the SARS-CoV-2 coronavirus outbreak, it's eager to place it on pharmacy shelves.

Neurocrine's stock rose by nearly 5.3% on Thursday, well outpacing the gains of the broader stock market.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Neurocrine Biosciences, Inc. Stock Quote
Neurocrine Biosciences, Inc.
NBIX
$106.97 (1.27%) $1.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.